HOME >> MEDICINE >> NEWS
Earlier treatment of perinatal HIV associated with decreased HIV progression, better outcomes

In a study in the May 11 JAMA, earlier treatment of children with HIV infection with ART is associated with less HIV progression and improved survival rates.

Worldwide, approximately 2.5 million children are infected with HIV, and approximately 1,700 new perinatal infections occur daily, according to background information in the article. In the United States, more than 9,300 HIV-infected children younger than 13 years have progressed to AIDS as of December 2003. While the Pediatric AIDS Clinical Trials Group (PACTG) 076 regimen has reduced perinatal transmission by 67 percent, prenatal combination ART has further reduced transmission to 2 percent or less. However, the impact of treatment on progression of perinatal HIV infection remains poorly characterized at the population level. Perinatal HIV infection may progress in 2 patterns: early, with a typical onset of age 4 months, or late, with a typical onset of age 6 years.

David R. Berk, M.D., of the Stanford University School of Medicine, Stanford, Calif., and colleagues conducted a study to determine the progression of HIV, survival, and distribution of category C (the most severe of three categories, dependent on symptomatic conditions) diagnoses in a perinatal population-based sample during different eras in prevention and management and in relation to early institution of any ART therapy. The researchers examined the trends in early progression of perinatal HIV infection among 205 HIV-infected children in Northern California born between January 1, 1988, and December 31, 2001, and followed up through age 3 years.

The researchers found that of 205 children, 134 (65 percent) received ART and/or prophylactic treatment against Pneumocystis jiroveci pneumonia. By age 3 years, 81 (40 percent) progressed to a category C diagnosis, 41 (51 percent) of whom died. Untreated children were significantly more likely to progress to a category C diagnosis (62 percent [44/71] untreated vs. 28 pe
'"/>

Contact: Krista Conger
650-725-5371
JAMA and Archives Journals
10-May-2005


Page: 1 2 3

Related medicine news :

1. Earlier periodontal treatment leads to lower medical costs
2. Spot on treatment for acne
3. New treatment boosts muscle function in myasthenia gravis
4. New treatment effective in counteracting cocaine-induced symptoms
5. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
6. Preventive treatments in elderly people needs rethinking
7. Osteoporosis screening and treatment may be cost-effective for selected older men
8. Quality of treatment guidelines
9. Green tea holds promise as new treatment for inflammatory skin diseases
10. Many heart attack patients still not getting emergency clot-busting treatment
11. Electric fields have potential as a cancer treatment

Post Your Comments:
(Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
(Date:10/22/2014)... The Louis W. Sullivan Institute ... distribute health information technology innovation to transform quality ... development of six key guiding principles of patient-centered ... These are an expansion of the Institute of ... is respectful of and responsive to individual patient ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most ... recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the ... the world. , “iPower is one of the most ... various kinds of useful products for new and old ... customer service and a number of features which will ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Lintelus, Inc., ... Sr. Vice President of Sales, will be speaking on ... Meetings Technology Expo on October 28, at the Holiday ... hosting a booth as well as a Tech Demo ... Meeting can create a more engaging event experience. , ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... only about half as likely as white women to become ... and the racial disparity persists even when donor eggs are ... patients became pregnant after IVF, compared to about 17 percent ... over two years to tease out the impact of race, ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
(Date:10/22/2014)... October 22, 2014 Oramed ... a clinical-stage pharmaceutical company focused on the development ... top-line clinical results from its Phase IIa clinical ... capsules, to treat type 1 diabetes. The trial was ... under a U.S. Food and Drug Administration ...
(Date:10/22/2014)... Colo. , Oct. 22, 2014   Surefire ... of infusion systems designed to maximize targeted delivery of ... pleased to announce that oncologist John R. Daniels ... Comprehensive Cancer Center, and surgical oncologist Steven C. ... have joined the Company,s Scientific Advisory Board (SAB).    ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... and dermatology therapies. PV-10, its novel investigational drug for ... the potential for systemic side effects. Its oncology focus ... liver. Provectus has completed phase 2 trials of PV-10 ... as a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
Cached News: